Enoxaparin Dosing Guidelines for Anticoagulation Therapy

Standard Prophylactic Dosing

• The American College of Cardiology recommends a standard dose of 40 mg subcutaneously once daily for venous thromboembolism prophylaxis in hospitalized medical patients with normal renal function 4, 1, 3
• For patients with severe renal impairment, the recommended dose is reduced to 30 mg subcutaneously once daily, as enoxaparin clearance decreases by 44% in severe renal impairment, leading to a 2-3 fold increased bleeding risk without dose adjustment 1, 2, 3

Standard Therapeutic Dosing

• The American Heart Association recommends a standard dose of 1 mg/kg subcutaneously every 12 hours for treatment of venous thromboembolism or acute coronary syndrome in patients with normal renal function 1, 3
• For patients with severe renal impairment, the recommended dose is reduced to 1 mg/kg subcutaneously once daily, as patients with CrCl <30 mL/min have 2.25 times higher odds of major bleeding with standard dosing 1, 2, 3

Critical Safety Considerations and Monitoring

• The American College of Chest Physicians recommends monitoring anti-Xa levels in all patients with CrCl <30 mL/min receiving prolonged treatment, with a target therapeutic anti-Xa range of 0.5-1.0 IU/mL for twice-daily dosing and >1.0 IU/mL for once-daily dosing 1, 2, 3

Alternative Anticoagulation Strategy

• The European Society of Cardiology recommends considering switching to unfractionated heparin for severe renal impairment requiring therapeutic anticoagulation, as UFH undergoes reticuloendothelial clearance and does not accumulate in renal failure 1, 2, 3